Shopping Cart
Remove All
Your shopping cart is currently empty
VTX-27 is a selective inhibitor of protein kinase C θ (PKC θ) (Kis: 0.08 nM and 16 nM for PKC θ and PKC δ).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $85 | - | In Stock | |
| 2 mg | $127 | - | In Stock | |
| 5 mg | $256 | - | In Stock | |
| 10 mg | $383 | - | In Stock | |
| 25 mg | $592 | - | In Stock | |
| 50 mg | $822 | - | In Stock | |
| 100 mg | $1,090 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $237 | - | In Stock |
| Description | VTX-27 is a selective inhibitor of protein kinase C θ (PKC θ) (Kis: 0.08 nM and 16 nM for PKC θ and PKC δ). |
| Targets&IC50 | PKCθ:0.08 nM (ki), PKCα:356 nM (ki), PKCδ:16 nM (ki) |
| In vitro | It has also been found that VTX-27 has good selectivity to other PKC family members, especially the classic isoforms (except for PKCβI, >1000 times, 200 times) and atypical isoforms (>10000 times). As expected, it is more challenging to obtain selectivity for more closely related novel PKC family members, which is 200 times more selective than PKCδ. |
| In vivo | VTX-27 demonstrates a superior PK profile characterized by low clearance (7 mL/min/kg), high oral bioavailability (65%), and a prolonged half-life (4.7 h). Following a single oral administration at doses of 6.25, 12.5, 25, and 50 mg/kg (e.g., at 25 mg/kg Cmax concentration 700 ng/mL), it effectively inhibits IL-2 production in a potent dose-dependent manner. |
| Molecular Weight | 418.9 |
| Formula | C20H24ClFN6O |
| Cas No. | 1321924-70-2 |
| Smiles | FC1=C(C=2C=3C(NN2)=NC=CC3)N=C(C(Cl)=C1)N4C[C@@]([C@](C(C)C)(C)O)(NCC4)[H] |
| Relative Density. | 1.342 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (298.4 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.55 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.